AlloVir reports Q1 net loss $41.2M; Phase 3 posoleucel trials on track for 2024

Kalaris Therapeutics, Inc.

2023-Q1 EPS reported -$0.44

Net loss of $41.2M ($0.44/share) vs $43.9M ($0.69/share) in Q1 2022.
Cash, cash equivalents and short-term investments were $202.6M as of March 31, 2023.
R&D expenses $30.7M, G&A $12.5M; FY 2023 operating expense guidance $150M-$170M excl. non-cash.
Three Phase 3 registrational trials of posoleucel in allo-HCT patients continue enrolling; data readouts expected in 2024.
Positive Phase 2 data for posoleucel in BK viremia in kidney transplant recipients to be presented at ATC 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kalaris Therapeutics, Inc. updated its fiscal year 2023 guidance (initiated).

Period: fiscal year 2023
Guidance: initiated
Result: guidance update

Exact text from the filing

For fiscal year 2023, AlloVir expects operating expenses to be in the range of $150 million to $170 million, excluding non-cash expenses.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kalaris Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: net income $41.2 million, EPS $0.44 per share.

Period: the first quarter ended March 31, 2023
Net income: $41.2 million
EPS: $0.44 per share
Result: reported results

Exact text from the filing

For the quarter ended March 31, 2023, net loss was $41.2 million or $0.44 per share compared with a net loss of $43.9 million or $0.69 per share for the quarter ended March 31, 2022.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Kalaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-135024

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.